Eli Lilly, the American pharmaceutical giant, said on Tuesday that it had received European approval to sell its new drug for treating Type 2 diabetes, putting pressure on its Danish rival Novo Nordisk, the market leader in its category.

The European Commission approved the drug, Trulicity, after a positive recommendation in September from the European Medicines Agency committee that reviews pharmaceutical products for human consumption, Lilly said in a statement from Indianapolis, where it is based. Trulicity will be in European pharmacies next year, the company said.

The drug, also known by the generic name dulaglutide, was cleared in September by the Food and Drug Administration for sale in the United States.

For more details, go to: http://www.nytimes.com/2014/11/26/business/international/eli-lilly-gets-european-approval-to-sell-trulicity-a-type-2-diabetes-drug.html?_r=0